FDA approved the first ophthalmic bevacizumab LYTENAVA for the treatment of wet AMD
FDA accepted Outlook Therapeutics' appeal and will approve LYTENAVA — a standardized bevacizumab for neovascular AMD. Analysis of consequences for the anti-VEGF market, pricing, and patients. Read more.
